- Home
- AIRT vs AADI Comparison
AIRT vs AADI Comparison
Compare AIRT & AADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- AADI
- Stock Information
- Founded
- AIRT 1980
- AADI 2011
- Country
- AIRT United States
- AADI United States
- Employees
- AIRT N/A
- AADI N/A
- Industry
- AIRT Air Freight/Delivery Services
- AADI Biotechnology: Pharmaceutical Preparations
- Sector
- AIRT Consumer Discretionary
- AADI Health Care
- Exchange
- AIRT Nasdaq
- AADI Nasdaq
- Market Cap
- AIRT 47.3M
- AADI 49.0M
- IPO Year
- AIRT N/A
- AADI N/A
- Fundamental
- Price
- AIRT $17.37
- AADI $2.11
- Analyst Decision
- AIRT
- AADI Hold
- Analyst Count
- AIRT 0
- AADI 3
- Target Price
- AIRT N/A
- AADI $1.75
- AVG Volume (30 Days)
- AIRT 23.2K
- AADI 114.7K
- Earning Date
- AIRT 11-12-2024
- AADI 11-06-2024
- Dividend Yield
- AIRT N/A
- AADI N/A
- EPS Growth
- AIRT N/A
- AADI N/A
- EPS
- AIRT N/A
- AADI N/A
- Revenue
- AIRT $284,091,000.00
- AADI $25,070,000.00
- Revenue This Year
- AIRT N/A
- AADI $8.10
- Revenue Next Year
- AIRT N/A
- AADI $8.54
- P/E Ratio
- AIRT N/A
- AADI N/A
- Revenue Growth
- AIRT N/A
- AADI 7.80
- 52 Week Low
- AIRT $12.53
- AADI $1.21
- 52 Week High
- AIRT $30.60
- AADI $5.70
- Technical
- Relative Strength Index (RSI)
- AIRT 52.40
- AADI 56.23
- Support Level
- AIRT $14.93
- AADI $1.98
- Resistance Level
- AIRT $20.93
- AADI $2.40
- Average True Range (ATR)
- AIRT 1.23
- AADI 0.11
- MACD
- AIRT 0.34
- AADI 0.01
- Stochastic Oscillator
- AIRT 41.45
- AADI 36.96
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About AADI Aadi Bioscience Inc.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.